“This is a necessary step given the significant impact these regulations will have on patient access to medicines and the future of Canada’s life sciences sector,” said IMC President Pamela Fralick. “For nearly two years, our industry has tried to work with Health Canada to find policy alternatives that would make medicines more affordable without jeopardizing the industry’s rationale to invest in Canada and patient access to new medicines.”
Despite repeated attempts, including by stakeholders from patient groups to life sciences ecosystem members, Health Canada was unwilling to make any meaningful changes to the final regulations. As a result, IMC has filed this judicial review application on the basis that the federal government does not have the authority to fundamentally alter the role of the PMPRB through the recent changes to the Patented Medicines Regulations.
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
For further information:
E-mail: [email protected]
SOURCE: Innovative Medicines Canada
View source version on accesswire.com: